Treatment
Cyclophosphamide clinical trials
We’re tracking 518 recruiting studies that include Cyclophosphamide, each written for real people, not researchers, below.
Recruiting studies
- NCT06518668Enrolling by invitationPhase 1
NKX019 cell therapy for lupus
This study tests a new therapy called NKX019, which uses specially engineered natural killer cells to target a protein on lupus cells. It is for people with moderate to severe lupus that has not responded to standard treatments, especially those with active kidney inflammation.
New York, New YorkAges 18–65 - NCT06500273RecruitingPhase 2
Cema-cel for high-risk lymphoma after first treatment
This trial tests a new treatment called cema-cel for people with large B-cell lymphoma who are in remission after first-line therapy but still have tiny amounts of cancer detected by a sensitive blood test. The goal is to prevent the cancer from coming back.
Gilbert, ArizonaAges 18 years+ - NCT06499025Enrolling by invitationEarly Phase 1
T-cell therapy for a type of AML with the AML1-ETO gene
This trial tests a personalized cell therapy that uses your own immune cells (T cells) to target a specific protein (AML1-ETO) found in certain AML cells. It is for patients whose leukemia has come back or not gone away after standard treatment.
Shenzhen, GuangdongAges 18–75 - NCT06486051RecruitingPhase 2
CAR T-cell therapy for adults with relapsed large B-cell lymphoma
This trial tests a new treatment called atlacabtagene autoleucel, which uses your own immune cells to fight the lymphoma. It's designed for people whose lymphoma has come back or not responded to initial treatments.
Auckland, AucklandAges 18–75 - NCT06481735RecruitingPhase 1/Phase 2
Modified donor CAR-T for B-cell leukemia
This trial tests a new type of CAR-T cell therapy for people with B-cell acute lymphoblastic leukemia that has returned or not responded to standard treatment. The CAR-T cells are made from a donor and modified to target the CD19 protein on leukemia cells.
Beijing, Beijing MunicipalityAges 16–70 - NCT06483048RecruitingPhase 1
MUC1-targeted T cells for relapsed ovarian cancer
This trial tests a new treatment using your own immune cells, modified to target a protein called MUC1 on ovarian cancer cells. It is for people with ovarian cancer that has come back or is resistant to standard treatments.
Scottsdale, ArizonaAges 18 years+ - NCT06468943Enrolling by invitationPhase 2
New drug combo for non-GCB diffuse large B-cell lymphoma
This trial tests a combination of three targeted drugs (polatuzumab vedotin, zanubrutinib, and R-CHP) for people newly diagnosed with a specific subtype of DLBCL called non-GCB. The goal is to see if this powerful mix can work better than standard treatment.
Suzhou, NanjingAges 18 years+ - NCT06474676RecruitingPhase 1
Modified immune cell therapy for advanced sarcoma
This trial tests a new treatment using your own immune cells (TILs) that have been modified to attack sarcoma tumors. It is for people with advanced soft tissue or bone sarcoma who have already tried at least one other therapy.
Houston, TexasAges 12 years+ - NCT06421948RecruitingPhase 1/Phase 2
Linperlisib and chidamide for PTCL
This trial tests two pills—linperlisib and chidamide—for people with a type of lymphoma called PTCL. The combination might work better together than either alone.
Zhengzhou, HenanAges 18–80 - NCT06434363RecruitingPhase 1/Phase 2
Cell therapy plus tafasitamab for autoimmune diseases
This trial tests a new cell therapy (AD-PluReceptor) combined with the drug tafasitamab for people with certain autoimmune diseases like systemic sclerosis, lupus, or chronic graft-versus-host disease. It aims to see if this treatment can help when standard therapies have failed.
Houston, TexasAges 18 years+ - NCT05658640RecruitingPhase 1/Phase 2
Testing trametinib and steroid plus chemo for relapsed blood cancers
This early-phase trial tests whether adding trametinib and dexamethasone to standard chemotherapy can improve outcomes for children whose blood cancer has come back or did not respond. Because it is a Phase 1/2 study, the main goal is to see safety and learn the best way to treat your specific cancer type.
ViennaAges 1–21 - NCT06401330RecruitingPhase 3
Personalized treatment for pediatric Wilms tumor
This study tailors treatment for children with Wilms tumor based on specific tumor features and risk factors. The goal is to give the right amount of therapy to each patient to minimize side effects while maintaining high cure rates.
Birmingham, AlabamaAges Up to 30 years - NCT06387121RecruitingPhase 2
Low-dose chemo plus immune drugs for new B-ALL
This trial tests a combination of low-dose chemotherapy and immune-targeted drugs for adults newly diagnosed with a specific type of leukemia. The goal is to find a treatment that is effective with fewer side effects.
Tianjin, Tianjin MunicipalityAges 18 years+ - NCT06383572RecruitingPhase 1/Phase 2
Modified immune cells for blood cancers after chemo
This trial tests a new type of immune cell (NK cell) that has been engineered to target a protein called PRAME found on some cancer cells. It is for people with certain types of blood cancer (AML, MDS, or CMML) that have come back or not responded to treatment.
Houston, TexasAges 18–80 - NCT06390319RecruitingPhase 2
Adding dasatinib or venetoclax for children with T-cell leukemia or lymphoma
This trial tests whether adding either dasatinib or venetoclax to standard chemotherapy can improve outcomes for children aged 1 to 18 with newly diagnosed T-cell acute lymphoblastic leukemia, lymphoblastic lymphoma, or mixed phenotype acute leukemia. It compares the effects of these added drugs to help doctors find better treatment options.
San Diego, CaliforniaAges 1–18 - NCT06364423RecruitingPhase 1/Phase 2
CAR T-cell therapy for CD19-positive leukemias and lymphomas
This trial tests a new immune therapy that uses your own cells (CAR T-cells) to find and attack cancer cells with the CD19 protein. It is for people with certain types of leukemia or lymphoma that have not responded to other treatments.
Bethesda, MarylandAges 18–120 - NCT06375993Enrolling by invitationPhase 1
Prula-cel for autoimmune diseases: a phase 1 study
This trial tests a new treatment called prulacabtagene leucel (prula-cel), which is a type of immune cell therapy (CAR T-cells) for people with certain autoimmune diseases. It aims to see if it can reset the immune system and reduce disease activity in conditions like lupus, scleroderma, vasculitis, or myositis.
Redwood City, CaliforniaAges 18–80 - NCT06345495RecruitingPhase 2
High-dose ruxolitinib and stem cell transplant for enlarged spleen in myelofibrosis
This trial tests a higher dose of ruxolitinib before a stem cell transplant for people with myelofibrosis who have an enlarged spleen. It aims to see if this approach helps the transplant work better.
Houston, TexasAges 18–75 - NCT06347068RecruitingPhase 1
CAR-T cell therapy for triple-negative breast cancer
This trial tests a new treatment using your own immune cells, modified to target a protein called B7-H3 on triple-negative breast cancer cells. It may help if other treatments haven't worked.
Chapel Hill, North CarolinaAges 18 years+ - NCT06319456RecruitingPhase 3
Study of lisaftoclax plus acalabrutinib for untreated CLL/SLL
This trial tests a new combination of two targeted drugs (lisaftoclax and acalabrutinib) against standard chemo-immunotherapy for people newly diagnosed with chronic lymphocytic leukemia or small lymphocytic lymphoma who need treatment. It aims to see if the combination works better.
Bengbu, AnhuiAges 18 years+ - NCT06326463RecruitingPhase 1
CAR T-cell therapy for CD70-positive blood cancers in children
This trial tests a special immune cell therapy (CAR T-cells) that targets a protein called CD70 on blood cancer cells. It is for children and young adults up to age 21 whose cancer has come back or hasn't gotten better with other treatments.
Memphis, TennesseeAges Up to 21 years - NCT06318897RecruitingPhase 2
Immunotherapy with chemo for early triple-negative breast cancer
This trial tests a combination of an immunotherapy drug (pembrolizumab) plus two chemotherapy drugs (carboplatin and paclitaxel) given before surgery for people with early-stage, triple-negative breast cancer. The goal is to see if this treatment helps shrink or eliminate the tumor before it's removed.
Houston, TexasAges 18 years+ - NCT06317662RecruitingPhase 2
Adding venetoclax and blinatumomab to chemo for infant leukemia
This trial tests adding two newer medicines (venetoclax and blinatumomab) to standard chemotherapy for infants with a specific type of leukemia. The goal is to see if this combination helps more babies stay cancer-free.
Birmingham, AlabamaAges Up to 12 months - NCT06308978RecruitingPhase 1
Study of FT819 for B-cell autoimmune diseases
This trial tests a new cell therapy, FT819, for people with certain autoimmune diseases like lupus, vasculitis, myositis, or scleroderma that haven't improved with at least two previous treatments. The goal is to see if it can help control the disease.
Beverly Hills, CaliforniaAges 12–70
Common questions
- Are there clinical trials studying Cyclophosphamide?
- Yes. Clin2 currently lists 518 recruiting studies that include Cyclophosphamide, drawn from the U.S. registry and rewritten for real people so you can see what each is testing and who it's for.
- How do I know if I qualify for a Cyclophosphamide trial?
- Each study lists its own eligibility criteria — rules about condition, age, and prior treatments. On every Clin2 trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Is Cyclophosphamide an approved treatment?
- A drug being studied in a trial may be investigational (still being tested) or already approved and being studied for a new use. Each study page explains what phase it's in. Clin2 does not provide medical advice — talk with your doctor about whether Cyclophosphamide or a specific trial is right for you.
Related treatments
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. A drug appearing here is being studied in a trial and may be investigational. Talk with your doctor about whether a specific treatment or trial is right for you.